![Graphite Bio, Inc. logo](/logos/GRPH.webp)
Graphite Bio, Inc.
NASDAQ:GRPH
Overview | Financials
Company Name | Graphite Bio, Inc. |
Symbol | GRPH |
Currency | USD |
Price | 3.18 |
Market Cap | 185,193,342 |
Dividend Yield | 64.78% |
52-week-range | 3.05 - 29.82 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Kimberlee Cobleigh Drapkin CPA, CPA |
Website | https://www.graphitebio.com |
An error occurred while fetching data.
About Graphite Bio, Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD